Drug Profile
AGM 130
Alternative Names: AGM 130Latest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator AnyGen
- Class Antineoplastics
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for phase-I development in Triple negative Breast-cancer in South Korea (IV)
- 11 Mar 2017 AnyGen has patents pending for AGM 130 in USA, Japan, Korea and Europe
- 10 Mar 2017 Phase-I clinical trials in Breast cancer in South Korea (IV) before March 2017 (AnyGen pipeline, March 2017)